Once a Silicon Valley pioneer in consumer genetic testing, 23andMe is now at the center of a high-stakes legal and financial ...

By Dietrich Knauth NEW YORK (Reuters) -Bankrupt genetic testing company 23andMe told a U.S. bankruptcy judge on Wednesday ...

There are standard solutions to the problem, but they are only partial solutions: In the past few months, I have written a ...

Bankrupt genetic testing firm 23andMe is seeking to reopen bidding on its assets, including over 15 million customer DNA ...

The founder of 23andMe, Anne Wojcicki, has asked a judge to reopen an auction for the genetic testing company, saying she has ...

However, the purchase price point may be pointing to a decline in the value ... the pharmaceutical company is capable of providing similar services that 23andMe once did for its customers.

Is this tech company behind CEO's bid for 23andMe genetic data? How Anne Wojcicki's group still could snag 23andMe How Anne ...

Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...

At its peak, the company was valued at $6 billion. While the market initially believed in the value of 23andMe's business model, its stock has been in decline for years, and the company owes ...

The company’s market value peaked at almost $6 billion after it went public in 2021, but 23andMe reported a 7% decline in revenue and losses of $174 million in the first nine months of its ...

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.